GlassScriptPhysician profile
Tae Soon Kim
NPI 1780627653
$380.32
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.39 · 2020: $14.66 · 2021: $277 · 2022: $36.38 · 2024: $18.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $224.76 | 2021 | |
| Lilly USA, LLC | $67.23 | 2020-2021 | |
| Amgen INC. | $36.38 | 2022 | |
| Fidia Pharma USA INC. | $21.24 | 2019 | |
| Glaxosmithkline, LLC. | $18.56 | 2024 | Shingrix, Arexvy |
| Scilex Pharmaceuticals INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tae Soon Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.